Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F14%3A00436140" target="_blank" >RIV/61388971:_____/14:00436140 - isvavai.cz</a>
Alternative codes found
RIV/67985823:_____/14:00436140
Result on the web
<a href="http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=2233569B1&KC=B1&FT=D&ND=4&date=20140625&DB=worldwide.espacenet.com&locale=en_EP" target="_blank" >http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=2233569B1&KC=B1&FT=D&ND=4&date=20140625&DB=worldwide.espacenet.com&locale=en_EP</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
Original language description
The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates topolypeptide derivatives suitable for eliciting an immune response in a host. The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. Said mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of also retaining the translocating activity of native CyaA through its N-terminal domain into target cells and furthermorehave a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
EE - Microbiology, virology
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
EP2233569
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Jun 25, 2014
Owner name
Institut Pasteur - Mikrobiologický ústav AV ČR, v. v. i. - Fyziologický ústav AV ČR,v. v. i.
Method of use
B - Výsledek je využíván orgány státní nebo veřejné správy
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence